CDX2: Linking Cell and Patient Fates in Colon Cancer

Eric R. Fearon, Emina H. Huang

Research output: Contribution to journalShort surveypeer-review

Abstract

Administering adjuvant chemotherapy to stage II colon cancer patients is controversial due to limited benefit observed for this subpopulation. Recently, Dalerba et al. (2016) identified a subgroup of stage II patients that might benefit from adjuvant chemotherapy based on lack of CDX2 expression in their cancer stem cells.

Original languageEnglish (US)
Pages (from-to)168-169
Number of pages2
JournalCell Stem Cell
Volume18
Issue number2
DOIs
StatePublished - Feb 4 2016
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Cell Biology

Fingerprint

Dive into the research topics of 'CDX2: Linking Cell and Patient Fates in Colon Cancer'. Together they form a unique fingerprint.

Cite this